OSR Holdings（OSRH）株式概要OSR Holdings, Inc.はヘルスケア持株会社で、米国、ドイツ、スイス、韓国で治療とヘルスケアソリューションのポートフォリオを開発している。 詳細OSRH ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性3/6配当金0/6リスク分析US市場と比較して、過去 3 か月間の株価の変動が非常に大きい過去1年間で株主の希薄化は大幅に進んだ 意味のある収益がありません ( $3M )意味のある時価総額がありません ( $17M )すべてのリスクチェックを見るOSRH Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.50597.2% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-10m3m2016201920222025202620282031Revenue US$2.6mEarnings US$477.7kAdvancedSet Fair ValueView all narrativesOSR Holdings, Inc. 競合他社CurisSymbol: NasdaqCM:CRISMarket cap: US$19.6mLongeveronSymbol: NasdaqCM:LGVNMarket cap: US$21.1mZeo ScientifiXSymbol: OTCPK:ZEOXMarket cap: US$14.2mHOOKIPA PharmaSymbol: OTCPK:HOOKMarket cap: US$14.9m価格と性能株価の高値、安値、推移の概要OSR Holdings過去の株価現在の株価US$0.5052週高値US$1.7952週安値US$0.38ベータ0.861ヶ月の変化-14.31%3ヶ月変化20.96%1年変化-56.72%3年間の変化-95.07%5年間の変化n/aIPOからの変化-95.03%最新ニュースReported Earnings • May 14First quarter 2026 earnings released: US$0.09 loss per share (vs US$1.05 loss in 1Q 2025)First quarter 2026 results: US$0.09 loss per share (improved from US$1.05 loss in 1Q 2025). Net loss: US$2.93m (loss narrowed 74% from 1Q 2025).お知らせ • May 12OSR Holdings, Inc., Annual General Meeting, Jun 18, 2026OSR Holdings, Inc., Annual General Meeting, Jun 18, 2026. Location: washington, seattle, United StatesNew Risk • Apr 29New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Revenue has declined by 18% over the past year. Shareholders have been substantially diluted in the past year (72% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$37m net loss next year). Revenue is less than US$5m (US$2.9m revenue). Market cap is less than US$100m (US$24.7m market cap).お知らせ • Mar 10OSR Holdings, Inc. Receives Additional Compliance Period to Regain Compliance with Nasdaq Listing RuleOn March 5, 2026, OSR Holdings, Inc. (the Company) received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (Nasdaq) notifying the Company that Nasdaq has granted the Company an additional 180 calendar day period, or until August 31, 2026, to regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share. As previously disclosed, on September 5, 2025, the Company received notice from Nasdaq that the closing bid price of the Company's common stock had fallen below the required minimum bid price of $1.00 per share for 30 consecutive business days and that the Company had been provided an initial 180 calendar day compliance period, or until March 4, 2026, to regain compliance. Nasdaq determined that the Company is eligible for the additional compliance period because the Company meets the continued listing requirement for the market value of publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market, with the exception of the minimum bid price requirement. If at any time during this additional compliance period the closing bid price of the Company's common stock is at least $1.00 per share for a minimum of 10 consecutive business days, Nasdaq will provide written confirmation that the Company has regained compliance with the minimum bid price requirement. The Company intends to monitor the closing bid price of its common stock and will consider available options to regain compliance with Nasdaq's minimum bid price requirement.Board Change • Dec 31High number of new and inexperienced directorsThere are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. 1 experienced director. No highly experienced directors. Chief Legal Officer & Director Jun Whang is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Sep 11OSR Holdings, Inc. Receives A Written Notice from the Listing Qualifications Department of the Nasdaq Stock Market Regarding Minimum Bid Price RequirementOn September 5, 2025, OSR Holdings, Inc. (the Company") received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (Nasdaq") indicating that the Company is not in compliance with the minimum bid price requirement set in Nasdaq Listing Rule 5550(a)(2), because the closing bid price of the Company's common stock has been below $1.00 per share for 30 consecutive business days. The notice has no immediate effect on the listing or trading of the Company's securities, which will continue to trade on The Nasdaq Capital Market under the symbols OSRH" and OSRHW." The Company has been provided an initial period of 180 calendar days, or until March 4, 2026, to regain compliance. If at any time during this period the closing bid price of the Company's common stock is at least $1.00 for a minimum of ten consecutive business days, Nasdaq will provide written confirmation that the Company has regained compliance. If the Company does not regain compliance by March 4, 2026, it may be eligible for an additional 180-day compliance period, provided that it meets the continued listing requirements for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market (other than the bid price requirement), and provides written notice to Nasdaq of its intent to cure the deficiency, including by means of a reverse stock split if necessary. If the Company is not eligible for the second compliance period, Nasdaq will provide notice that the Company's securities are subject to delisting, which determination the Company may appeal. The Company intends to actively monitor the closing bid price of its common stock and will consider available options to regain compliance with the Nasdaq Listing Rules.最新情報をもっと見るRecent updatesReported Earnings • May 14First quarter 2026 earnings released: US$0.09 loss per share (vs US$1.05 loss in 1Q 2025)First quarter 2026 results: US$0.09 loss per share (improved from US$1.05 loss in 1Q 2025). Net loss: US$2.93m (loss narrowed 74% from 1Q 2025).お知らせ • May 12OSR Holdings, Inc., Annual General Meeting, Jun 18, 2026OSR Holdings, Inc., Annual General Meeting, Jun 18, 2026. Location: washington, seattle, United StatesNew Risk • Apr 29New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Revenue has declined by 18% over the past year. Shareholders have been substantially diluted in the past year (72% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$37m net loss next year). Revenue is less than US$5m (US$2.9m revenue). Market cap is less than US$100m (US$24.7m market cap).お知らせ • Mar 10OSR Holdings, Inc. Receives Additional Compliance Period to Regain Compliance with Nasdaq Listing RuleOn March 5, 2026, OSR Holdings, Inc. (the Company) received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (Nasdaq) notifying the Company that Nasdaq has granted the Company an additional 180 calendar day period, or until August 31, 2026, to regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share. As previously disclosed, on September 5, 2025, the Company received notice from Nasdaq that the closing bid price of the Company's common stock had fallen below the required minimum bid price of $1.00 per share for 30 consecutive business days and that the Company had been provided an initial 180 calendar day compliance period, or until March 4, 2026, to regain compliance. Nasdaq determined that the Company is eligible for the additional compliance period because the Company meets the continued listing requirement for the market value of publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market, with the exception of the minimum bid price requirement. If at any time during this additional compliance period the closing bid price of the Company's common stock is at least $1.00 per share for a minimum of 10 consecutive business days, Nasdaq will provide written confirmation that the Company has regained compliance with the minimum bid price requirement. The Company intends to monitor the closing bid price of its common stock and will consider available options to regain compliance with Nasdaq's minimum bid price requirement.Board Change • Dec 31High number of new and inexperienced directorsThere are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. 1 experienced director. No highly experienced directors. Chief Legal Officer & Director Jun Whang is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Sep 11OSR Holdings, Inc. Receives A Written Notice from the Listing Qualifications Department of the Nasdaq Stock Market Regarding Minimum Bid Price RequirementOn September 5, 2025, OSR Holdings, Inc. (the Company") received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (Nasdaq") indicating that the Company is not in compliance with the minimum bid price requirement set in Nasdaq Listing Rule 5550(a)(2), because the closing bid price of the Company's common stock has been below $1.00 per share for 30 consecutive business days. The notice has no immediate effect on the listing or trading of the Company's securities, which will continue to trade on The Nasdaq Capital Market under the symbols OSRH" and OSRHW." The Company has been provided an initial period of 180 calendar days, or until March 4, 2026, to regain compliance. If at any time during this period the closing bid price of the Company's common stock is at least $1.00 for a minimum of ten consecutive business days, Nasdaq will provide written confirmation that the Company has regained compliance. If the Company does not regain compliance by March 4, 2026, it may be eligible for an additional 180-day compliance period, provided that it meets the continued listing requirements for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market (other than the bid price requirement), and provides written notice to Nasdaq of its intent to cure the deficiency, including by means of a reverse stock split if necessary. If the Company is not eligible for the second compliance period, Nasdaq will provide notice that the Company's securities are subject to delisting, which determination the Company may appeal. The Company intends to actively monitor the closing bid price of its common stock and will consider available options to regain compliance with the Nasdaq Listing Rules.New Risk • Aug 26New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 31% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$1.8m free cash flow). Share price has been highly volatile over the past 3 months (31% average weekly change). Revenue has declined by 48% over the past year. Shareholders have been substantially diluted in the past year (434% increase in shares outstanding). Revenue is less than US$1m (US$105k revenue). Minor Risks Less than 3 years of financial data is available. Market cap is less than US$100m (US$11.1m market cap).お知らせ • Aug 20OSR Holdings, Inc., Annual General Meeting, Sep 17, 2025OSR Holdings, Inc., Annual General Meeting, Sep 17, 2025. Location: 5 penn plaza, 19th floor, new york 1001., new york United StatesReported Earnings • Aug 19Second quarter 2025 earnings released: EPS: US$0.02 (vs US$1.83 loss in 2Q 2024)Second quarter 2025 results: EPS: US$0.02 (up from US$1.83 loss in 2Q 2024). Net income: US$331.4k (up US$3.79m from 2Q 2024).お知らせ • Jul 02OSR Holdings, Inc. Announces Resignation of Sang Hyun Kim as A Member of the Board of DirectorsOSR Holdings, Inc. announced that on June 26, 2025, Sang Hyun Kim provided notice of his resignation as a member of the Board of Directors, including his role as an independent director of the company. Mr. Kim’s resignation took immediate effect and was not the result of any dispute or disagreement with the Company on any matter relating to its operations, policies or practices.お知らせ • May 16OSR Holdings, Inc. announced delayed 10-Q filingOn 05/15/2025, OSR Holdings, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 24OSR Holdings, Inc. Auditor Raises 'Going Concern' DoubtOSR Holdings, Inc. filed its 10-K on Apr 22, 2025 for the period ending Dec 31, 2024. In this report its auditor, WithumSmith+Brown, PC , gave an unqualified opinion expressing doubt that the company can continue as a going concern.お知らせ • Apr 04OSR Holdings, Inc. announced that it expects to receive $80 million in fundingOSR Holdings, Inc. entered into purchase agreement to sell common stock up to gross proceeds $80,000,000 on April 3, 2025. The transaction includes participation from White Lion GBM Innovation Fund.お知らせ • Mar 25OSR Holdings, Inc. Appoints Constance Höfer as Chief Scientific OfficerOSR Holdings, Inc. announced the appointment of Dr. Constance Höfer as its new Chief Scientific Officer (CSO). Dr. Höfer, a seasoned leader in drug development with over 20 years of experience in oncology and immunology, will oversee OSR Holdings' scientific strategy and innovation pipeline. Dr. Höfer joins OSR Holdings from Merck Healthcare, where she led global programs spanning from preclinical to late-stage clinical development. Prior to Merck, she held senior leadership positions at Sandoz Biopharmaceuticals, Priaxon AG, and Medigene AG, playing a key role in advancing therapeutic programs across various modalities, including New Biological Entities (NBEs), New Chemical Entities (NCEs), nucleotides, and viral and cell-based therapies. Coupled with her extensive industry experience and a PhD in Pharmacology from the University of Newcastle, Dr. Höfer has a strong foundation in clinical pharmacology and translational medicine, ensuring a seamless transition from early-stage research to successful clinical development. Dr. Höfer's appointment reinforces OSR Holdings' commitment to advancing cutting-edge therapeutic solutions and strengthening its R&D capabilities. Her expertise will enhance the company's ability to identify and develop promising drug candidates, streamline clinical development, and improve regulatory success rates. By leveraging her experience in biologics, small molecules, and other advanced therapeutic modalities, OSR Holdings aims to accelerate the translation of innovative research into clinical applications, expand its footprint in oncology and immunology, and drive long-term value for both patients and stakeholders.株主還元OSRHUS BiotechsUS 市場7D-11.9%1.2%1.0%1Y-56.7%34.9%28.7%株主還元を見る業界別リターン: OSRH過去 1 年間で34.9 % の収益を上げたUS Biotechs業界を下回りました。リターン対市場: OSRHは、過去 1 年間で28.7 % のリターンを上げたUS市場を下回りました。価格変動Is OSRH's price volatile compared to industry and market?OSRH volatilityOSRH Average Weekly Movement23.8%Biotechs Industry Average Movement11.0%Market Average Movement7.2%10% most volatile stocks in US Market16.4%10% least volatile stocks in US Market3.1%安定した株価: OSRHの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: OSRHの weekly volatility ( 24% ) は過去 1 年間安定していますが、依然としてUSの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイトn/a22Peter Hwangwww.osr-holdings.comヘルスケア持株会社であるOSRホールディングス社は、米国、ドイツ、スイス、韓国で治療薬とヘルスケアソリューションのポートフォリオを開発している。同社は、第2相臨床試験を完了した膠芽腫の免疫腫瘍学候補薬VXM01を含む免疫療法製品、メソセリン治療薬VXM04、ウィルムス腫瘍タンパク質（WT1）治療薬VXM06、カルチノ胚性抗原（CEA）治療薬VXM08、PD-L1治療薬VXM10などの前臨床段階の製品を開発している。また、脊椎固定術の臨床段階にあるDRT-102と変形性関節症の前臨床段階にあるDRT-101からなるデザイン・オーグメンテッド（DA）生物製剤も開発している。さらに、同社は神経血管介入医療機器とシステムの販売も行っている。OSRホールディングスはワシントン州ベルビューに本社を置いている。もっと見るOSR Holdings, Inc. 基礎のまとめOSR Holdings の収益と売上を時価総額と比較するとどうか。OSRH 基礎統計学時価総額US$16.90m収益（TTM）-US$9.55m売上高(TTM)US$2.63m6.3xP/Sレシオ-1.7xPER（株価収益率OSRH は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計OSRH 損益計算書（TTM）収益US$2.63m売上原価US$2.08m売上総利益US$547.74kその他の費用US$10.10m収益-US$9.55m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-0.29グロス・マージン20.84%純利益率-363.30%有利子負債／自己資本比率3.9%OSRH の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 13:26終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋OSR Holdings, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Andrew WhiteEmerging Growth Research LLC
Reported Earnings • May 14First quarter 2026 earnings released: US$0.09 loss per share (vs US$1.05 loss in 1Q 2025)First quarter 2026 results: US$0.09 loss per share (improved from US$1.05 loss in 1Q 2025). Net loss: US$2.93m (loss narrowed 74% from 1Q 2025).
お知らせ • May 12OSR Holdings, Inc., Annual General Meeting, Jun 18, 2026OSR Holdings, Inc., Annual General Meeting, Jun 18, 2026. Location: washington, seattle, United States
New Risk • Apr 29New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Revenue has declined by 18% over the past year. Shareholders have been substantially diluted in the past year (72% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$37m net loss next year). Revenue is less than US$5m (US$2.9m revenue). Market cap is less than US$100m (US$24.7m market cap).
お知らせ • Mar 10OSR Holdings, Inc. Receives Additional Compliance Period to Regain Compliance with Nasdaq Listing RuleOn March 5, 2026, OSR Holdings, Inc. (the Company) received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (Nasdaq) notifying the Company that Nasdaq has granted the Company an additional 180 calendar day period, or until August 31, 2026, to regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share. As previously disclosed, on September 5, 2025, the Company received notice from Nasdaq that the closing bid price of the Company's common stock had fallen below the required minimum bid price of $1.00 per share for 30 consecutive business days and that the Company had been provided an initial 180 calendar day compliance period, or until March 4, 2026, to regain compliance. Nasdaq determined that the Company is eligible for the additional compliance period because the Company meets the continued listing requirement for the market value of publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market, with the exception of the minimum bid price requirement. If at any time during this additional compliance period the closing bid price of the Company's common stock is at least $1.00 per share for a minimum of 10 consecutive business days, Nasdaq will provide written confirmation that the Company has regained compliance with the minimum bid price requirement. The Company intends to monitor the closing bid price of its common stock and will consider available options to regain compliance with Nasdaq's minimum bid price requirement.
Board Change • Dec 31High number of new and inexperienced directorsThere are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. 1 experienced director. No highly experienced directors. Chief Legal Officer & Director Jun Whang is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Sep 11OSR Holdings, Inc. Receives A Written Notice from the Listing Qualifications Department of the Nasdaq Stock Market Regarding Minimum Bid Price RequirementOn September 5, 2025, OSR Holdings, Inc. (the Company") received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (Nasdaq") indicating that the Company is not in compliance with the minimum bid price requirement set in Nasdaq Listing Rule 5550(a)(2), because the closing bid price of the Company's common stock has been below $1.00 per share for 30 consecutive business days. The notice has no immediate effect on the listing or trading of the Company's securities, which will continue to trade on The Nasdaq Capital Market under the symbols OSRH" and OSRHW." The Company has been provided an initial period of 180 calendar days, or until March 4, 2026, to regain compliance. If at any time during this period the closing bid price of the Company's common stock is at least $1.00 for a minimum of ten consecutive business days, Nasdaq will provide written confirmation that the Company has regained compliance. If the Company does not regain compliance by March 4, 2026, it may be eligible for an additional 180-day compliance period, provided that it meets the continued listing requirements for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market (other than the bid price requirement), and provides written notice to Nasdaq of its intent to cure the deficiency, including by means of a reverse stock split if necessary. If the Company is not eligible for the second compliance period, Nasdaq will provide notice that the Company's securities are subject to delisting, which determination the Company may appeal. The Company intends to actively monitor the closing bid price of its common stock and will consider available options to regain compliance with the Nasdaq Listing Rules.
Reported Earnings • May 14First quarter 2026 earnings released: US$0.09 loss per share (vs US$1.05 loss in 1Q 2025)First quarter 2026 results: US$0.09 loss per share (improved from US$1.05 loss in 1Q 2025). Net loss: US$2.93m (loss narrowed 74% from 1Q 2025).
お知らせ • May 12OSR Holdings, Inc., Annual General Meeting, Jun 18, 2026OSR Holdings, Inc., Annual General Meeting, Jun 18, 2026. Location: washington, seattle, United States
New Risk • Apr 29New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Revenue has declined by 18% over the past year. Shareholders have been substantially diluted in the past year (72% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$37m net loss next year). Revenue is less than US$5m (US$2.9m revenue). Market cap is less than US$100m (US$24.7m market cap).
お知らせ • Mar 10OSR Holdings, Inc. Receives Additional Compliance Period to Regain Compliance with Nasdaq Listing RuleOn March 5, 2026, OSR Holdings, Inc. (the Company) received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (Nasdaq) notifying the Company that Nasdaq has granted the Company an additional 180 calendar day period, or until August 31, 2026, to regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share. As previously disclosed, on September 5, 2025, the Company received notice from Nasdaq that the closing bid price of the Company's common stock had fallen below the required minimum bid price of $1.00 per share for 30 consecutive business days and that the Company had been provided an initial 180 calendar day compliance period, or until March 4, 2026, to regain compliance. Nasdaq determined that the Company is eligible for the additional compliance period because the Company meets the continued listing requirement for the market value of publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market, with the exception of the minimum bid price requirement. If at any time during this additional compliance period the closing bid price of the Company's common stock is at least $1.00 per share for a minimum of 10 consecutive business days, Nasdaq will provide written confirmation that the Company has regained compliance with the minimum bid price requirement. The Company intends to monitor the closing bid price of its common stock and will consider available options to regain compliance with Nasdaq's minimum bid price requirement.
Board Change • Dec 31High number of new and inexperienced directorsThere are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. 1 experienced director. No highly experienced directors. Chief Legal Officer & Director Jun Whang is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Sep 11OSR Holdings, Inc. Receives A Written Notice from the Listing Qualifications Department of the Nasdaq Stock Market Regarding Minimum Bid Price RequirementOn September 5, 2025, OSR Holdings, Inc. (the Company") received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (Nasdaq") indicating that the Company is not in compliance with the minimum bid price requirement set in Nasdaq Listing Rule 5550(a)(2), because the closing bid price of the Company's common stock has been below $1.00 per share for 30 consecutive business days. The notice has no immediate effect on the listing or trading of the Company's securities, which will continue to trade on The Nasdaq Capital Market under the symbols OSRH" and OSRHW." The Company has been provided an initial period of 180 calendar days, or until March 4, 2026, to regain compliance. If at any time during this period the closing bid price of the Company's common stock is at least $1.00 for a minimum of ten consecutive business days, Nasdaq will provide written confirmation that the Company has regained compliance. If the Company does not regain compliance by March 4, 2026, it may be eligible for an additional 180-day compliance period, provided that it meets the continued listing requirements for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market (other than the bid price requirement), and provides written notice to Nasdaq of its intent to cure the deficiency, including by means of a reverse stock split if necessary. If the Company is not eligible for the second compliance period, Nasdaq will provide notice that the Company's securities are subject to delisting, which determination the Company may appeal. The Company intends to actively monitor the closing bid price of its common stock and will consider available options to regain compliance with the Nasdaq Listing Rules.
New Risk • Aug 26New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 31% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$1.8m free cash flow). Share price has been highly volatile over the past 3 months (31% average weekly change). Revenue has declined by 48% over the past year. Shareholders have been substantially diluted in the past year (434% increase in shares outstanding). Revenue is less than US$1m (US$105k revenue). Minor Risks Less than 3 years of financial data is available. Market cap is less than US$100m (US$11.1m market cap).
お知らせ • Aug 20OSR Holdings, Inc., Annual General Meeting, Sep 17, 2025OSR Holdings, Inc., Annual General Meeting, Sep 17, 2025. Location: 5 penn plaza, 19th floor, new york 1001., new york United States
Reported Earnings • Aug 19Second quarter 2025 earnings released: EPS: US$0.02 (vs US$1.83 loss in 2Q 2024)Second quarter 2025 results: EPS: US$0.02 (up from US$1.83 loss in 2Q 2024). Net income: US$331.4k (up US$3.79m from 2Q 2024).
お知らせ • Jul 02OSR Holdings, Inc. Announces Resignation of Sang Hyun Kim as A Member of the Board of DirectorsOSR Holdings, Inc. announced that on June 26, 2025, Sang Hyun Kim provided notice of his resignation as a member of the Board of Directors, including his role as an independent director of the company. Mr. Kim’s resignation took immediate effect and was not the result of any dispute or disagreement with the Company on any matter relating to its operations, policies or practices.
お知らせ • May 16OSR Holdings, Inc. announced delayed 10-Q filingOn 05/15/2025, OSR Holdings, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 24OSR Holdings, Inc. Auditor Raises 'Going Concern' DoubtOSR Holdings, Inc. filed its 10-K on Apr 22, 2025 for the period ending Dec 31, 2024. In this report its auditor, WithumSmith+Brown, PC , gave an unqualified opinion expressing doubt that the company can continue as a going concern.
お知らせ • Apr 04OSR Holdings, Inc. announced that it expects to receive $80 million in fundingOSR Holdings, Inc. entered into purchase agreement to sell common stock up to gross proceeds $80,000,000 on April 3, 2025. The transaction includes participation from White Lion GBM Innovation Fund.
お知らせ • Mar 25OSR Holdings, Inc. Appoints Constance Höfer as Chief Scientific OfficerOSR Holdings, Inc. announced the appointment of Dr. Constance Höfer as its new Chief Scientific Officer (CSO). Dr. Höfer, a seasoned leader in drug development with over 20 years of experience in oncology and immunology, will oversee OSR Holdings' scientific strategy and innovation pipeline. Dr. Höfer joins OSR Holdings from Merck Healthcare, where she led global programs spanning from preclinical to late-stage clinical development. Prior to Merck, she held senior leadership positions at Sandoz Biopharmaceuticals, Priaxon AG, and Medigene AG, playing a key role in advancing therapeutic programs across various modalities, including New Biological Entities (NBEs), New Chemical Entities (NCEs), nucleotides, and viral and cell-based therapies. Coupled with her extensive industry experience and a PhD in Pharmacology from the University of Newcastle, Dr. Höfer has a strong foundation in clinical pharmacology and translational medicine, ensuring a seamless transition from early-stage research to successful clinical development. Dr. Höfer's appointment reinforces OSR Holdings' commitment to advancing cutting-edge therapeutic solutions and strengthening its R&D capabilities. Her expertise will enhance the company's ability to identify and develop promising drug candidates, streamline clinical development, and improve regulatory success rates. By leveraging her experience in biologics, small molecules, and other advanced therapeutic modalities, OSR Holdings aims to accelerate the translation of innovative research into clinical applications, expand its footprint in oncology and immunology, and drive long-term value for both patients and stakeholders.
